BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | $145.25M-85.1% |
| Revenue (ttm) | n/a |
| Net Income | -$171.53M |
| EPS | $0.53 |
| Shares Out | 80.25M |
| PE Ratio | 3.42 |
| Forward PE | -0.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 450,960 |
| Open | $1.87 |
| Previous Close | $1.86 |
| Day's Range | $1.78 - $1.94 |
| 52-Week Range | $1.78 - $14.87 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | $20.91(+1055.20%) |
| Earnings Date | Nov 10, 2026 |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
9 firms rating BBOT in the last 3 months, one vote each. Issuer-paid research is not counted.
$BBOT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BBOT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BBOT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BBOT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BBOT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BBOT from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from BBOT’s recent data — informational, not investment advice
